Small integrin-binding proteins as serum markers for prostate cancer detection

Clinical Cancer Research

Volumn 15, Issue 16, 2009, Pages 5199-5207

  Jain, Alka ^a   McKnight, Dianalee A ^b   Fisher, Larry W ^b   Humphreys, Elizabeth B ^a   Mangold, Leslie A ^a   Partin, Alan W ^a   Fedarko, Neal S ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c JHAAC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BONE SIALOPROTEIN; COMPLEMENTARY DNA; DENTIN SIALOPHOSPHOPROTEIN; INTEGRIN; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; OSTEOPONTIN; SIALOPROTEIN; SMALL INTEGRIN BINDING LIGAND N LINKED GLYCOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR BIOPSY; VALIDATION STUDY; WESTERN BLOTTING;

BIOLOGICAL MARKERS; BLOOD PROTEINS; CARCINOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; INTEGRINS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; PROTEIN BINDING; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 69349099669     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0783     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Maattanen L, Hakama M, Tammela TL, et al. Specificity of serumprostate-specific antigen determination in the Finnish prostate cancer screening trial. Br J Cancer 2007;96:56-60. (Pubitemid 46094639)
3. Perrotti M. Understanding PSA and prostate cancer risk assessment. N J Med 2001;98:35-38
4. Altwein J, Ekman P, Barry M, et al. How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium. Urology 1997;49:66-76. (Pubitemid 27157685)
5. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008;8:212-226 (Pubitemid 351301854)
6. Ogbureke KU, Fisher LW. SIBLING expression patterns in duct epithelia reflect the degree of metabolic activity. J Histochem Cytochem 2007;55:403-409
7. Fisher LW, Jain A, Tayback M, Fedarko NS. Small integrin binding ligand N-linked glycoprotein (SIBLING) gene family expression in different cancers. Clin Cancer Res 2004;10: 8501-8511 (Pubitemid 40053416)
8. Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J 2004;18: 734-736
9. Jain A, Fisher LW, Fedarko NS. Bone sialoprotein binding to matrix metalloproteinase-2 alters enzyme inhibition kinetics. Biochemistry 2008; 47:5986-5995 (Pubitemid 351770028)
10. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295: 2387-2392 (Pubitemid 34270240)
11. Fisher LW, McBride OW, Termine JD, Young MF. Human bone sialoprotein. Deduced protein sequence and chromosomal localization. J Biol Chem1990;265:2347-2351
12. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 1986;83:8819-8823 (Pubitemid 17223492)
13. Hirst KL, Ibaraki-O'Connor K, Young MF, Dixon MJ. Cloning and expression analysis of the bovine dentin matrix acidic phosphoprotein gene. J Dent Res 1997;76:754-760 (Pubitemid 127732664)
14. de Vega S, Iwamoto T, Nakamura T, et al. TM14 is a new member of the fibulin family (fibulin-7) that interacts with extracellular matrix molecules and is active for cell binding. J Biol Chem200 7; 282:30878-30888
15. Ogbureke KU, Fisher LW. Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res 2004;83:664-670
16. Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 2000;275:16666-16672 (Pubitemid 30398895)
17. Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS. Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem2002;277:13700-13708
18. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001;280:460-465 (Pubitemid 32912812)
19. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serumbone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-4066 (Pubitemid 34044628)
20. Jain A, Fedarko NS, Collins MT, et al. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serumph osphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab 2004;89:4158-4161 (Pubitemid 39071529)
21. Bautista DS, Saad Z, Chambers AF, et al. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem 1996;29:231-239 (Pubitemid 26142072)
22. Bramwell VH, Doig GS, Tuck AB, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006;12:3337-3343
23. Petrik D, Lavori PW, Cao H, et al. Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol 2006;24: 5291-5297 (Pubitemid 46631376)
24. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bonemarkers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007;67:330-340 (Pubitemid 46255790)
25. Ramankulov A, Lein M, Kristiansen G, Meyer HA, Loening SA, Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 2007;133:643-652 (Pubitemid 47077056)
26. Wu CY, Wu MS, Chiang EP, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 2007;56:782-789
27. Kadkol SS, Lin AY, Barak V, et al. Osteopontin expression and serumlevels inmetastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci 2006;47:802-806 (Pubitemid 46768309)
28. Martinetti A, Bajetta E, Ferrari L, et al. Osteoprotegerin and osteopontin serumvalues in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer 2004;11:771-779 (Pubitemid 40065550)
29. MacDougall M, Simmons D, Luan X, Nydegger J, Feng J, Gu TT. Dentin phosphoprotein and dentin sialoprotein are cleavage products expressed froma single transcript coded by a gene on human chromosome 4. Dentin phosphoprotein DNA sequence determination. J Biol Chem1997;272:835-842
30. Pashayan N, Powles J, Brown C, Duffy SW. Incidence trends of prostate cancer in East Anglia, before and during the era of PSA diagnostic testing. Br J Cancer 2006;95:398-400. (Pubitemid 44187606)
31. Andriole GL, Grubb RL III, Buys SS, et al. Mortality results froma randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-1319
32. Waltregny D, Bellahcene A, Van Riet I, et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998;90:1000-1008 (Pubitemid 28340442)
33. Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006;118: 2255-2261
34. Khodavirdi AC, Song Z, Yang S, et al. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 2006;66:883-888 (Pubitemid 43165954)
35. Chaplet M, Waltregny D, Detry C, Fisher LW, Castronovo V, Bellahcene A. Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness. Int J Cancer 2006;118:850-856 (Pubitemid 43157660)
36. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-261 (Pubitemid 29244499)
37. Ogbureke KU, Fisher LW. Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int 2005;68: 155-166
38. Banu NA, Azim FA, Kamal M, Rumi MA, Barua AR, Khan KH. Inflammation and glandular proliferation in hyperplastic prostates: association with prostate specific antigen value. Bangladesh Med Res Counc Bull 2001;27:79-83. (Pubitemid 34904859)
39. Loeb S, Gashti SN, Catalona WJ. Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). Urol Oncol 2009;27:64-66
40. Veis A, Perry A. The phosphoprotein of the dentin matrix. Biochemistry 1967;6:2409-2416
41. Qin C, Baba O, Butler WT. Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 2004;15:126-136
42. Steiglitz BM, Ayala M, Narayanan K, George A, Greenspan DS. Bone morphogenetic protein-1/ tolloid-like proteinases process dentin matrix protein-1. J Biol Chem2004;279:980-986
43. Yamakoshi Y, Hu JC, Iwata T, Kobayashi K, Fukae M, Simmer JP. Dentin sialophosphoprotein is processed by MMP-2 and MMP-20 in vitro and in vivo. J Biol Chem2006;281: 38235-38243
44. Xi Z, Klokk TI, Korkmaz K, et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 2004; 64:2365-2370 (Pubitemid 38523888)
45. Zeng H, Xiao Y, Lu G, Chen Y. Immunohistochemical studies of the expression of matrix metalloproteinase- 2 and metalloproteinase-9 in human prostate cancer. J Huazhong Univ Sci Technol Med Sci 2003;23:373-4, 9.